The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Arwi G, Chhor L, Malipatil V

Recrudescence of Natalizumab-Induced Pneumonitis and Peripheral Hypereosinophilia: Case Report and Literature Review.

Respirology case reports 2025 Apr;13;e70191 — 2025 Apr — e70191

Yasuda Y, Nagano T, Tachihara M, Chihara N, Umezawa K, Katsurada N, Yamamoto M, Sekiguchi K, Kobayashi K, Nishimura Y

Eosinophilic Pneumonia Associated With Natalizumab In A Patient With Multiple Sclerosis: A Case Report And Literature Review.

Therapeutics and clinical risk management 2019;15;1283-1289 — 2019 — 1283-1289

Curto E, Munteis-Olivas E, Balcells E, Domínguez-Álvarez MM

Pulmonary eosinophilia associated to treatment with natalizumab.

Annals of thoracic medicine 2016 Jul-Sep;11;224-6 — 2016 Jul-Sep — 224-6